Baxter wins FDA nod for multifocal motor neuropathy treatment; The waiting game continues with SCOTUS health reform law decision;

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: Yet another reason why device and Dx companies are turning to China. Item | Follow @MarkHFierce

 @DamianFierce: Teleflex dropped $30M on an MIT spin-out for its safety-boosting device coating. Story | Follow @DamianFierce

> GE ($GE) has extended its strategic relationship with Australia's Nanosonics with a new $7.5 million investment. Nanosonics is developing an ultrasound transducer disinfecting system. Release

> Greatbatch Medical opened a new 80,000-square-foot orthopaedic manufacturing center in Fort Wayne, IN. Release

> Baxter International ($BAX) gained FDA approval to use its Gammagard Liquid 10% (immune globulin infusion) as a treatment for multifocal motor neuropathy, the first treatment of its kind for the patient group approved in the U.S. Release

> Seegene, a diagnostic company based in Maryland and South Korea, is launching a test that detects, genotypes and quantifies 19 high-risk and 9 low-risk genotypes of the human papilloma virus. Release

> Berg Pharma has signed a deal with the Parkinson's Institute to investigate the cause of the disease and develop diagnostics for it. More

> Tower Semiconductor and Italian company RedCat Devices have develop new radiation hard integrated circuits, which can be used, in part, to produce medical devices sterilized with high doses of gamma radiation. The circuits also can enable medical device tracking. Story

Biotech News

 @FierceBiotech: : Immunotherapies make a comeback at Big | Follow @FierceBiotech

 @JohnCFierce: Merck Serono and Compugen are starting up a new biomarkers co. for drug-induced toxicity. Release | Follow @JohnCFierce

 @RyanMFierce: FierceBiotech IT lands in Philly for DIA summit, let me know how we're doing. More | Follow @RyanMFierce

> FDA rejects blockbuster Eliquis bid, asks Pfizer, BMS for trial clarification. News

> Price curmudgeons at NICE prep early-stage advice for VCs. Story

> Lexicon boasts of positive results in PhIIb diabetes study. Article

> Ventrus shares clobbered after failed PhIII forces it to regroup. Report

Pharma News

 @FiercePharma: Andrew Witty's letter to EU urges reference pricing, parallel trade changes to keep meds flowing to Greece, et al. Report | Follow @FiercePharma

> FDA hits Shire with early nod for Adderall XR copycat. Story

> Xarelto, Pradaxa find reprieve in Eliquis delay. Article

> Teva's patent victory on Copaxone boosts franchise long-term. More

Biotech IT News

> Why Microsoft's Yammer buyout matters in pharma. Article

> Merck Serono, Compugen form startup to catch drug toxicity early. More

> Oracle rolls out cloud apps for clinical trial recruitment. Story

> Bay Area startup delivers clinical trials analytics from the cloud. News

And Finally... Still no word yet as of late Monday morning as to the Supreme Court's decision on the constitutionality of the national health reform law. But that hasn't stopped pundits from speculating all weekend about how the SCOTUS decision. Depending on what it is, it will affect the device industry and many other healthcare sectors. Story

Suggested Articles

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.